CHIGENOVO

Beijing, China · Founded 2016 · Privately Held (backing)

Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. CHIGENOVO is based in Beijing, China and was founded in 2016. Its last reported valuation was $110 million in Mar 2022. It has raised $41 million.

Last reported valuation
$110.4M
Oct 2026
Priced at
—
Total raised
$41.0M
Last round
—

Who backs CHIGENOVO?

10 investors
InvestorType
Cowin CapitalVenture capital
Puhua CapitalOther
Lapam CapitalVenture capital
Lotus Lake VenturesVenture capital
Huayi CapitalVenture capital
Junci InvestmentGrowth equity
Kunlun CapitalFamily office
Longmen Capital—
Wedo Venture Partners—
Yingke Capital—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

CHIGENOVO investors

10 investors are on record for CHIGENOVO, including Cowin Capital, Puhua Capital, Lapam Capital and Lotus Lake Ventures. By type, the record holds 4 venture capital firms, 1 family office and 1 growth equity firm.

Free account
More of CHIGENOVO with a free account
  • ·Watch CHIGENOVO: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 10 firms already write checks for companies like CHIGENOVO. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View